A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 E6 antigens in women being studied for abnormal pap smear results

Journal of Lower Genital Tract Disease

Volumn 14, Issue 2, 2010, Pages 124-129

  Nakagawa, Mayumi ^a   Gupta, Sushil K ^a   Coleman, Hannah N ^a   Sellers, Matthew A ^a   Banken, Joseph A ^a   Greenfield, William W ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Human papillomavirus; Pap smear; Squamous intraepithelial lesion; T cells; Vaccine

Indexed keywords

HUMAN PAPILLOMAVIRUS ANTIGEN E6; HUMAN PAPILLOMAVIRUS E7 ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CERVIX UTERI; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; VAGINAL SMEARS; YOUNG ADULT;

EID: 77950981865     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3181c6f01e     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts &Figures 2009. Atlanta, GA: America Cancer Society; 2009.
2. World Health Organization. Global Estimates for Health Situation Assessment and Projections. 1990:29-30.
3. World Health Organization. GLOBOCAN (2002). Available at: http://www-dep.iarc.fr/globocan/database.htm. 2009. Accessed on October 20, 2008.
4. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991;67: 547-56. (Pubitemid 121001469)
5. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992;89:4442-6.
6. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36. (Pubitemid 120035062)
7. Schlegel R, Phelps WC, Zhang YL, Barbosa M. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J 1988;7: 3181-7.
8. Storey A, Pim D, Murray A, Osborn K, Banks L, Crawford L. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 1988;7:1815-20.
9. Pirisi L, Yasumoto S, Feller M, Doniger J, DiPaolo J. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol 1987;61:1061-6. (Pubitemid 17044016)
10. Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13: 324-7. (Pubitemid 38222568)
11. Munoz N, Bosch X, De Sanjose S, Herrero R, Castellsague X, Shah K, et al. Epidemiologic classification of human papillomavirus type associated with cervical cancer. N Engl J Med 2003;348:518-27. (Pubitemid 36159887)
12. Nakagawa M, Kim KH, Moscicki AB. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol 2005;12:1003-5.
13. Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK, et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000;182:595-8. (Pubitemid 30651059)
14. Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002;11: 483-8. (Pubitemid 34517944)
15. Höpfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000;356:1985-6.
16. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, Verheijen RH, Stukart MJ, Meijer CJ, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000; 88:92-8.
17. Steele JC, Mann CH, Rookes S, Rollason T, Murphy D, Freeth MG, et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 2005;93:248-59. (Pubitemid 41133212)
18. Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun 2006;6:9.
19. De Jong A, Van Der Burg SH, Kwappenberg KM, Van Der Hulst JM, Franken KL, Geluk A, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002;62:472-9. (Pubitemid 34106421)